Quince Therapeutics, Inc. Shareholders' Equity
Quince Therapeutics, Inc. (QNCX) had Shareholders' Equity of -$35.32 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent -$35.32M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $15.67M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$35.71M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.06M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$35.32M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $15.67M 10-Q · filed 2026-08-14 |
| 2025-12-31 | -$35.71M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $1.06M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $11.74M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $18.58M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $30.15M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $44.93M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $46.97M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $74.18M 10-Q · filed 2025-08-11 |
| 2023-12-31 | $85.08M 10-K · filed 2026-04-10 |
| 2023-09-30 | $83.13M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $86.88M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $90.20M 10-Q · filed 2024-08-13 |
| 2022-12-31 | $100.59M 10-K · filed 2025-03-24 |
| 2022-09-30 | $104.53M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $111.53M 10-Q · filed 2023-11-14 |
| 2022-03-31 | $106.38M 10-Q · filed 2023-08-03 |
| 2021-12-31 | $118.59M 10-K · filed 2024-04-01 |
| 2021-09-30 | $132.65M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $142.08M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $156.48M 10-Q · filed 2022-08-09 |
| 2020-12-31 | $172.26M 10-K · filed 2023-03-15 |
| 2020-09-30 | $188.01M 10-Q · filed 2021-10-29 |
| 2020-06-30 | $205.47M 10-Q · filed 2021-10-29 |
| 2020-03-31 | $218.04M 10-Q · filed 2021-08-06 |
| 2019-12-31 | $115.48M 10-K · filed 2022-03-01 |
| 2019-09-30 | $127.29M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $136.22M 10-Q · filed 2020-11-12 |
| 2019-03-31 | -$38.03M 10-Q · filed 2020-08-14 |
| 2018-12-31 | -$32.63M 10-K · filed 2022-03-01 |
| 2018-09-30 | -$29.25M 10-Q · filed 2019-11-12 |
| 2018-06-30 | -$26.74M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$23.64M 10-Q · filed 2019-08-09 |
| 2017-12-31 | -$20.28M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |